Trial Profile
Exit Interviews to Assess Impact of Infusion Frequency in Hemophilia A
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Feb 2018
Price :
$35
*
At a glance
- Drugs Damoctocog alfa pegol (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Sponsors Bayer
- 01 Feb 2018 Status changed from active, no longer recruiting to completed.
- 13 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 11 Oct 2017 Planned End Date changed from 10 Nov 2017 to 15 Dec 2017.